文献速递脑血管病认知障碍与痴呆

脑淀粉样血管病的核心脑脊液生物标志物特征:一项Meta分析

Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis.
PubMed 文献 · Neurology · 2018-01-31

该系统检索PubMed并纳入3项研究(5个CAA队列,59例患者;健康对照94例;AD队列158例),采用随机效应Meta分析比较脑脊液Aβ42、Aβ40、t-tau和p-tau浓度比值。CAA与对照相比Aβ42、Aβ40、t-tau有差异,CAA与AD相比Aβ40、t-tau、p-tau有差异,但作者指出需在更大CAA队列中分析。

要点

  • CAA患者脑脊液Aβ42和Aβ40较健康对照降低,t-tau较对照升高。
  • CAA与AD鉴别时,Aβ40在CAA中显著降低,而Aβ42无差异。
  • t-tau和p-tau在CAA中均低于AD患者。

核心结论

  • 脑脊液Aβ42、Aβ40、t-tau和p-tau的特定模式可能作为CAA的分子生物标志物,但需要在更大CAA队列中进行分析。

研究设计与样本

  • 系统检索PubMed,纳入报告症状性散发性CAA队列与健康对照及AD患者脑脊液生物标志物数据的合格研究,采用基于均值比(RoM)的随机效应Meta分析评估标志物性能。
  • 共纳入3项研究,包含5个CAA患者队列(n=59例)、健康对照(n=94例)和AD队列(n=158例)。

主要发现

  • CAA与健康对照比较:脑脊液Aβ42的RoM为0.49(95%CI 0.38-0.64,p<0.003),Aβ40的RoM为0.70(95%CI 0.63-0.78,p<0.0001),t-tau的RoM为1.54(95%CI 1.15-2.07,p=0.004),p-tau的RoM为1.24(95%CI 0.99-1.54,p=0.062)。
  • CAA与AD比较:脑脊液Aβ40的RoM为0.76(95%CI 0.69-0.83,p<0.0001),Aβ42的RoM为1.00(95%CI 0.81-1.23,p=0.970)。
  • CAA与AD比较:t-tau的平均脑脊液比值为0.63(95%CI 0.54-0.74,p<0.0001),p-tau为0.60(95%CI 0.50-0.71,p<0.0001)。

局限性

  • 作者结论指出需要在更大CAA队列中进行分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To perform a meta-analysis of 4 core CSF biomarkers (β-amyloid [Aβ]42, Aβ40, total tau [t-tau], and phosphorylated tau [p-tau]) to assess which of these are most altered in sporadic cerebral amyloid angiopathy (CAA). METHODS: We systematically searched PubMed for eligible studies reporting data on CSF biomarkers reflecting amyloid precursor protein metabolism (Aβ42, Aβ40), neurodegeneration (t-tau), and tangle pathology (p-tau) in symptomatic sporadic CAA cohorts vs controls and patients with Alzheimer disease (AD). Biomarker performance was assessed in random-effects meta-analysis based on ratio of mean (RoM) biomarker concentrations: (1) in patients with CAA vs healthy controls and (2) in patients with CAA vs patients with AD. RoM >1 indicates higher biomarker concentration in patients with CAA vs comparison population and RoM <1 indicates higher concentration in comparison groups. RESULTS: Three studies met inclusion criteria. These comprised 5 CAA patient cohorts (n = 59 patients) vs healthy controls (n = 94 cases) and AD cohorts (n = 158). Three core biomarkers differentiated CAA from controls: CSF Aβ42 (RoM 0.49, 95% confidence interval [CI] 0.38-0.64, p < 0.003), Aβ40 (RoM 0.70, 95% CI 0.63-0.78, p < 0.0001), and t-tau (RoM 1.54, 95% CI 1.15-2.07, p = 0.004); p-tau was marginal (RoM 1.24, 95% CI 0.99-1.54, p = 0.062). Differentiation between CAA and AD was strong for CSF Aβ40 (RoM 0.76, 95% CI 0.69-0.83, p < 0.0001), but not Aβ42 (RoM 1.00; 95% CI 0.81-1.23, p = 0.970). For t-tau and p-tau, average CSF ratios in patients with CAA vs patients with AD were 0.63 (95% CI 0.54-0.74, p < 0.0001) and 0.60 (95% CI 0.50-0.71, p < 0.0001), respectively. CONCLUSION: Specific CSF patterns of Aβ42, Aβ40, t-tau, and p-tau might serve as molecular biomarkers of CAA, but analyses in larger CAA cohorts are needed.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Charidimou A, Friedrich JO, Greenberg SM, et al. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis. Neurology. 2018. PMID: 29386280. doi:10.1212/WNL.0000000000005030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。